Back

Safety and efficacy of dronedarone in overweight and obesity: a post-hoc analysis of the ATHENA trial

1 April 2025 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Clinical perspective on atrial fibrillation care Rhythm Control, Antiarrhythmic Drugs EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Associate Professor Mate Vamos

University of Szeged, Szeged (Hungary)

5 More presentations in this session

Presentation thumbnail
Obstructive sleep apnea phenotypes associated with atrial fibrillation
Doctor M. Van den Broek (Eindhoven, NL)
Abstract Slides Video
Presentation thumbnail
The acute clinical effects of rhythm control on elderly patients with long-standing atrial fibrillation, severe tricuspid regurgitation, and right heart failure: a multicenter prospective cohort study
Doctor F. Besiroglu (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
longest AF episode duration: a new indicator of AF burden?
Ms E. Schuijt (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Discrimination of atrial fibrillation burden using clinical and cardiac imaging data
Mr A. Gasser (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Impact of right or left sided radiation therapy for breast cancer in patients with atrial fibrillation on procedural findings and follow-up results of RF-catheter ablation
Doctor M. Tydecks (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical perspective on atrial fibrillation care

The Event

Event poster

EHRA 2025

1 April 2025 13:30 CET
You may be interested in
thumbnail
Congress Presentation
Association of body mass index with arrhythmia progression and outcomes in patients with subclinical atrial fibrillation: insights from the ARTESiA trial
thumbnail
Congress Presentation
Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe
thumbnail
Congress Presentation
Comparative analysis of antiarrhythmic drugs following atrial fibrillation ablation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources